Capmatinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Capmatinib
Accession Number
DB11791
Type
Small Molecule
Groups
Approved, Investigational
Description

Capmatinib has been used in trials studying the treatment of Melanoma, Gliosarcoma, Solid Tumors, Colorectal Cancer, and Hepatic Impairment, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
INC280 / INCB-28060 FREE BASE
Categories
Not Available
UNII
TY34L4F9OZ
CAS number
1029712-80-8
Weight
Average: 412.428
Monoisotopic: 412.144787354
Chemical Formula
C23H17FN6O
InChI Key
LIOLIMKSCNQPLV-UHFFFAOYSA-N
InChI
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
IUPAC Name
2-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide
SMILES
CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25145656
PubChem Substance
347828140
ChemSpider
25069712
BindingDB
50146167
ChEMBL
CHEMBL3188267
Wikipedia
Incyte

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentCMET-dysregulated Advanced Solid Tumors2
1RecruitingTreatmentColorectal Cancers / Glioblastoma Multiforme (GBM) / Gliosarcoma / Renal Cell Adenocarcinoma1
1RecruitingTreatmentEGFR-mutant Non-small Cell Lung Cancer1
1RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentCMET Dysegulation Advanced Solid Tumors1
1TerminatedTreatmentMetastatic Colorectal Cancers / Squamous Cell Carcinoma of Head and Neck (SCCHN) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
1, 2TerminatedTreatmentC-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM1
2Active Not RecruitingTreatmentAdenocarcinoma Lung Cancer / Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma1
2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma With c-MET Dysregulation1
2Active Not RecruitingTreatmentMelanoma1
2CompletedTreatmentALK Fusion Protein Expression / BRAF wt Allele / Invasive Skin Melanoma / Melanoma / MET Fusion Gene Positive / NRAS wt Allele / NTRK1 Fusion Positive / NTRK2 Fusion Positive / NTRK3 Fusion Positive / RET Fusion Positive / ROS1 Fusion Positive / Stage III Cutaneous Melanoma AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v71
2RecruitingTreatmentLung Cancer Metastatic / Malignancies / MET Gene Mutation1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)4
2RecruitingTreatmentMalignant Non-small Cell Neoplasm of Lung Stage IV1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentPapillary Renal Cell Carcinoma / Renal Cancers1
2WithdrawnTreatmentAdvanced Hepatocellular Carcinoma1
2WithdrawnTreatmentCarcinoma NOS / Lung Cancer Non-Small Cell Cancer (NSCLC)1
3Not Yet RecruitingHealth Services ResearchSoft Tissue Sarcoma (STS)1
4RecruitingTreatmentAdvanced Solid Tumors Which Are cMET-dependent1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00529 mg/mLALOGPS
logP3.04ALOGPS
logP2.96ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.77ChemAxon
pKa (Strongest Basic)4.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area85.07 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity125.27 m3·mol-1ChemAxon
Polarizability42.1 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Not Available
Direct Parent
Quinolines and derivatives
Alternative Parents
2-halobenzoic acids and derivatives / Benzamides / Imidazo[1,2-a][1,2,4]triazines / Benzoyl derivatives / Fluorobenzenes / N-substituted imidazoles / 1,2,4-triazines / Aryl fluorides / Pyridines and derivatives / Vinylogous halides
show 8 more
Substituents
Quinoline / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Imidazo[1,2-a][1,2,4]triazine / Benzamide / Benzoic acid or derivatives / Benzoyl / Halobenzene / Fluorobenzene / N-substituted imidazole
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:48 / Updated on June 04, 2019 07:27